JP4677033B2 - Maitake extract and composition for promoting sebum production containing the same - Google Patents

Description

  The present invention relates to a novel maitake extract and a composition for promoting sebum production containing the same.

  Sebaceous glands attach to the skin, secrete oily substances called sebum, and form an impermeable membrane on the epidermis surface. Sebum consists of a lipid mixture and contains triglycerides, squalene, aliphatic waxes, free fatty acids, cholesterols and the like.

  Sebum plays an important role in maintaining the moisture retention of the epidermis, providing moisture and flexibility to the epidermis, and promoting the strength of the skin. Sebum also has the effect of preventing the skin from being damaged by ultraviolet rays and protecting the skin from foreign substances, allergens and the like.

  When sebum production decreases due to aging, drug administration, etc., the elasticity and strength of the epidermis will decrease, and the resistance to damage will also decrease. In addition, the reduction in sebum production causes diseases such as dry skin.

  As active ingredients for promoting sebum production, esters of linoleic acid with amides or sugars (Patent Document 1) and branched chain amino acids (Patent Document 2) are known.

As an extract of Maitake, an extract by water or an aqueous solvent such as an extract by water or hot water (Patent Documents 3 to 6) or an extract by water-containing ethanol (Patent Documents 7 and 8) is known. Extracts of maitake with water or an aqueous solvent include carcinogen inhibitors (Patent Literature 4), antioxidants (Patent Literature 5), antifungal agents (Patent Literature 6), and enzyme inhibitors of tyrosinase and α-amylase (Patent Literature). 8) can be used.
JP-T-2006-504752 JP-T-2002-521320 JP-A-11-75768 Japanese Patent Laid-Open No. 2001-97881 Japanese Patent Laid-Open No. 2005-220087 JP 2004-189737 A JP-A-8-131133 JP 2000-319192 A

  The present invention is to provide a novel maitake extract and a composition containing the same that more effectively promote the production of sebum.

  As a result of intensive studies to solve the above problems, the present inventors have found that a pure ethanol extract of dried maitake has an excellent effect of promoting sebum production, leading to the present invention.

That is, the present invention is as follows.
(1) Maitake extract obtained by extracting dry maitake with pure ethanol;
(2) The maitake extract according to (1), wherein the moisture content of the dried maitake is 8% by weight or less;
(3) Maitake extract according to (1) or (2), wherein the pure ethanol contains 99.0% by volume or more of ethanol;
(4) A composition for promoting sebum production, comprising the maitake extract according to any one of (1) to (3);
(5) The composition according to (4), which is in the form of a cosmetic;
(6) The composition according to (4), which is in the form of a medicine.

  According to the present invention, the production of sebum can be effectively promoted, so that it is possible to effectively improve skin disorders / abnormalities and diseases caused by a decrease in sebum.

It is a photograph which shows the influence of the maitake extract and Agaricus extract with respect to lipid droplet formation in a sebaceous gland cell. It is a figure which shows the amount of sebum in the sebaceous cell processed with the maitake extract and the Agaricus extract. It is a figure which shows the effect of the maitake extract and Agaricus extract with respect to TG production of a sebaceous gland cell. It is a photograph which shows the effect of the maitake extract on the sebum accumulation of sebaceous glands. The black ellipses in the tissue sections indicate sebaceous glands (▲). It is a photograph which shows the effect of Agaricus extract with respect to sebum accumulation of a sebaceous gland. The black ellipses in the tissue sections indicate sebaceous glands (▲). It is a figure which shows the amount of sebum in the sebaceous cell processed with the maitake extract and the Agaricus extract. It is a figure which shows the sebum composition in the hamster sebaceous gland cell cultured in the presence of the maitake extract. ChoE, cholesterol ester (corresponding to cholesterol palmitate used as standard lipid); WaxE, wax ester (corresponding to palmityl palmitic acid used as standard lipid); TG, triacylglycerol (tripalmitin used as standard lipid) FFA, free fatty acid (corresponding to palmitic acid used as standard lipid); Cho, cholesterol (corresponding to cholesterol used as standard lipid). For statistical processing, the significance test between each processing by Fisher's multivariate analysis of variance method was used. It is the photograph of the skin before the treatment of the test subject 5 by the maitake extract containing cream.

  The present invention relates to a maitake extract obtained by extracting dry maitake with pure ethanol.

  The maitake in the present invention refers to a mushroom belonging to the genus Maitake mushroom, and examples include maitake (Grifola frondosa), white maitake (Grifola albicans), choreimaitake (Grifola umbellatus), and Griffola gigantean. The maitake in the present invention is preferably a maitake, which is a Griphora frontosa. Maitake may be either a fruit body or a mycelium, but a fruit body is preferred.

  The dried maitake, the raw material for extraction, refers to maitake having a moisture content of 10% by weight or less. The dried maitake preferably has a water content of 8% by weight or less, more preferably 7% by weight or less. Dry maitake can be obtained by dehydrating and drying raw maitake by any method (for example, sun drying, heat drying, vacuum drying, freeze drying, etc.). The dry maitake is preferably in the form of a powder.

  Pure ethanol in the present invention refers to ethanol containing 98.0% by volume or more of ethanol at 15 ° C. Pure ethanol preferably contains 99.0% by volume or more, more preferably 99.5% by volume or more of ethanol.

  Extraction of dry maitake with pure ethanol is performed by adding pure ethanol to dry maitake, which is a raw material, and then stirring at room temperature or under heating for a certain period of time. The heating temperature is usually a temperature below the boiling point of ethanol, but can also be a temperature below 120 ° C. in a closed container. A preferable extraction temperature is room temperature (room temperature). Although extraction time is not specifically limited, For example, it is about 5 minutes-10 hours. Extraction can be performed once or more than once.

  The amount of pure ethanol used in the extraction with respect to dry maitake is 100 to 1000 parts by weight, preferably 200 to 600 parts by weight, more preferably 300 to 500 parts by weight with respect to 100 parts by weight of dry maitake.

  After the extraction treatment, a pure ethanol extract can be obtained by separation means such as filtration with filter paper or filter cloth or centrifugation.

  The pure ethanol extract of maitake in the present invention may be in the above ethanol extract. Alternatively, the pure ethanol extract may be in the form of an extract obtained by completely or partially removing ethanol from the extract by a conventional method. That is, it may be an extract powder substantially free of ethanol or an extract extract containing 1 to 50% by weight of ethanol. An extract containing 10 to 15% by weight of ethanol is a preferred embodiment because of its good storage stability. The pure ethanol extract is obtained in a yield of 2 to 10% by weight, more specifically 3 to 5% by weight (as solids) based on dry maitake. The active ingredient in the pure ethanol extract is unknown, but the pure ethanol extract contains phospholipids and plant steroids.

  The present invention includes a composition for promoting sebum production comprising the extract.

  The composition of the present invention promotes sebum production, keeps the skin moisturized, moisturizes and softens the epidermis, promotes the strength of the skin, prevents damage to the epidermis due to ultraviolet rays, The skin can also be protected from foreign substances and allergens. Therefore, the present invention includes a composition for promoting sebum production comprising the above extract in the form of a cosmetic.

  The composition of the present invention in the form of a cosmetic may contain conventional carriers, excipients, additives and the like formulated in the cosmetic. It can be used as cosmetics for preventing rough skin, improving skin texture, improving skin flexibility, improving skin moisture retention and the like. Cosmetic dosage forms include face wash (face wash cream, foam, gel cosmetics, etc.), skin conditioning (lotion, serum, etc.), protection (milk, moisture cream, etc.), pack, oil, massage cosmetics. , Base makeup (foundation, white powder, etc. sunscreen, tanning cosmetics, etc.), point makeup (lipstick, eyeshadow, eyeliner, etc.), bathing (soap, body shampoo, bathing cosmetics, etc.), suncare (sun Screen, tanning cosmetics, etc.), and for hair growth / hair growth (hair growth, hair tonic, etc.). An effective amount of maitake extract, for example, 0.1 to 99.9% by weight, preferably 1 to 99% by weight in terms of extract, is blended with these cosmetics. In the remaining part, a conventional carrier, excipient, additive or the like is blended.

  Furthermore, the extract in the present invention has an improving effect on skin disorders or skin diseases resulting from a decrease in sebum production. Therefore, this invention includes the composition for promoting the sebum production containing the said extract in the form of an external medicine.

  The composition of the present invention in the form of an external medicine can contain conventional carriers, excipients, additives and the like blended with the medicine. Examples of skin disorders or skin diseases resulting from a decrease in sebum production include xeroderma, sebum-reducing dermatitis, monetary dermatitis, and atopic dermatitis. Examples of pharmaceutical dosage forms include solutions, suspensions, lotions, creams, ointments, gels, and the like. An effective amount, for example, 0.1 to 99.9% by weight, preferably 1 to 99%, of a maitake extract is blended with these external medicines. In the remaining part, a conventional carrier, excipient, additive or the like is blended.

Conventional carriers, excipients, or additives blended in cosmetics or medicines include solvents, vegetable oils (eg, almond oil, castor oil, cocoa butter, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil) Edible oils such as palm oil, peanut oil, poppy seed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, and tea seed oil), mineral oil, fatty oil, liquid paraffin, buffering agent, preservative, wetting agent, Examples include chelating agents, antioxidants, stabilizers, emulsifiers, suspending agents, gel forming agents, ointment bases, suppository bases, penetration enhancers, fragrances, and skin protection agents.
Solvents include but are not limited to water, alcohol, polyethylene glycol, propylene glycol, glycerol, liquid polyalkylsiloxanes and mixtures thereof.

Buffering agents include, but are not limited to, citric acid, acetic acid, tartaric acid, lactic acid, hydrogen phosphate, diethylamine, and mixtures thereof.
Wetting agents include, but are not limited to, glycerin, propylene glycol, pentylene glycol, sorbitol, lactic acid, urea, BG (1,3-butylene glycol), soy sterol, and mixtures thereof. .

Chelating agents include, but are not limited to sodium EDTA, citric acid and mixtures thereof.
Antioxidants include, but are not limited to, butylated hydroxyanisole (BHA), ascorbic acid and its derivatives, tocopherol and its derivatives, cysteine, and mixtures thereof.

  The emulsifiers include natural rubber (eg, acacia gum), tragacanth gum, xanthan gum; natural phosphatide (eg, soy lecithin); sorbitan monooleate derivative; wool fat; wool alcohol; sorbitan ester; monoglyceride; fatty alcohol (eg behenyl alcohol); Fatty acid esters (for example, triglycerides of fatty acids such as glyceryl tri (capryl / capric acid), glyceryl stearate (SE)); and mixtures thereof, but are not limited to these.

  Suspending agents include cellulose and its derivatives (eg carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc.), carrageenan, acacia gum, gum arabic, tragacanth and mixtures thereof. There is no limit.

  Gel bases and thickening ingredients include liquid paraffin, polyethylene, fatty oil, colloidal silica or aluminum, zinc soap, glycerol, propylene glycol, tragacanth, carboxyvinyl polymer, magnesium silicate-aluminum, hydrophilic polymer (eg starch Cellulose derivatives such as carboxymethylcellulose, hydroxyethylcellulose and other cellulose derivatives), water-swellable hydrocolloids, carrageenan, hyaluronic acid salts (eg hyaluronic acid gels selectively containing sodium chloride), alginate esters (eg propylene alginate) Glycol) and mixtures thereof, but are not limited thereto.

Ointment base includes beeswax, paraffin, cetanol, cetyl palmitate, cetearyl alcohol, polyglyceryl-10 stearate, stearic acid, PEG-150 stearate, vegetable oil, fatty acid sorbitan ester, polyethylene glycol, fatty acid sorbitan ester and oxidized Examples include, but are not limited to, condensation products with ethylene (for example, polyoxyethylene sorbitan monooleate) and mixtures thereof.
Hydrophobic ointment bases include, but are not limited to paraffins, vegetable oils, animal fats, synthetic glycerides, waxes, lanolin, liquid polyalkylsiloxanes and mixtures thereof.

  The hydrophilic ointment base includes, but is not limited to, solid macrogol (polyethylene glycol). Further, conventional carriers, excipients, or additives include squalane, lecithin, hydrogenated lecithin, ascorbyl tetrahexyldecanoate, allantoin, glycyrrhizic acid 2K, glycosyl trehalose, hydrolyzed hydrogenated starch hydrolyzed collagen rose extract, Dimethicone, caprylyl glycol, betaine, sodium stearoyl glutamate, Novara oil, batyl alcohol, hydroproxyproline and the like.

  Since the extract in the present invention activates sebaceous cells, the present invention also includes a composition for activating sebaceous cells containing the extract.

  EXAMPLES Hereinafter, although an Example etc. demonstrate this invention, this invention is not limited to this.

[Example 1] Production of maitake extract 4000 g of pure maitake (water content: 99.5 vol% or more) was added to 1000 g of sterilized dry powder of maitake (water content: 6 wt%, maitake made by Hokuto Co., Ltd.) Extraction was performed with stirring at a temperature of 20 ° C. for 18 hours. The residue was removed by centrifugation, and the resulting supernatant was filtered through filter paper. Ethanol was evaporated and removed from the obtained filtrate to obtain a pure ethanol extract of maitake (yield 43.2 g, internal solid content 37.2 g and ethanol 6.0 g).

[Test example] Sebum production promoting action of pure ethanol extract of maitake (method)
1. In vitro experimental method 1-1 Hamster sebaceous cell culture method 1-1-1 Isolation of hamster sebaceous gland The left and right auricles of male golden hamster (5 weeks old: purchased from Japan SLC) were excised, and penicillin G (100 units / ml) and dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with streptomycin sulfate (100 μg / ml) and left at 4 ° C. for 1 hour or more, then a phosphate buffer Washed with (PBS (−)). The hair around the auricle was cut, chopped to about 5 × 5 mm, and left in a 2.4 units / ml dispase solution (manufactured by Godo Shusei Co., Ltd.) at 4 ° C. for 13.5 hours. After the dispase treatment, the epidermis is peeled off from the auricle with tweezers, and the dermis including the sebaceous glands is sebocyte growth (SG) medium [6% (v / v) fetal calf serum (manufactured by Nichirei Biosciences, Inc.) / 2 % (V / v) human serum (ICN Biomedical) /0.68 mM L-glutamine / 100 units / ml penicillin G / 100 μg / ml streptomycin sulfate / DMEM / F-12] and sebaceous glands under a stereomicroscope Isolated.

1-1-2 Hamster Sebaceous Gland Tissue Culture Mouse 3T3 cells (purchased from Riken Cell Development Bank) were treated with mitomycin C for 4 hours, seeded in a 60 mm culture dish at ¹ × 10 ³ cells / cm ² , and hamster fat A feeder cell layer for culturing glandular cells was used. The isolated sebaceous glands were adhered onto the feeder cell layer using tweezers and cultured until nearly confluent under 37 ° C., 5% CO ₂ conditions. For cell culture, a medium in which EGF (10 ng / ml) was added to SG medium was used, and the medium was changed every two days.

1-1-3 Passage of Hamster Sebaceous Cells Hamsters that proliferated and expanded from tissue pieces after removing mouse 3T3 cells in the feeder cell layer using 0.02% (w / v) EDTA / PBS (−) solution Sebaceous cells were detached from the culture dish using a 0.25% (w / v) trypsin / 0.02% (w / v) EDTA / PBS (−) solution and subcultured. In all experiments, cells having a passage number of 3 were used.

1-2 Treatment Method The maitake extract (100, 200) obtained in Example 1 in the presence or absence of insulin (10 nM) (manufactured by Sigma-Aldrich) from the day after seeding hamster sebaceous cells in a 35 mm culture dish. And 400 μg / ml) or Agaricus extract (Kyowa Hakko Group, Kyowa Agaricus) 100, 200 and 400 μg / ml) (6% fetal calf serum / 2% human serum / 0.68 mM L-glutamine / 100 units / The cells were treated with ml penicillin G / 100 μg / ml streptomycin sulfate / DMEM / F-12). The same treatment was performed after 3 days, and the cells were further cultured for 3 days. In all experiments, cells having a passage number of 3 were used.

1-3 Oil red O staining method Isopropanol solution containing 0.3% Oil red O (manufactured by Sigma-Aldrich) and purified water are mixed at 3: 2 (v: v), and then a sealed ultrasonic cell crusher Was sonicated for 15 minutes. After standing at room temperature for 10 minutes, the filtered supernatant was used as Oil red O staining solution. After washing the cells with PBS (−), a fixative [4% paraformaldehyde / PBS (−)] was added and fixed at room temperature for 1 hour. After fixation, the cells were washed with distilled water, Oil red O staining solution was added and stained at 37 ° C. for 15 minutes. After staining, the cells were washed with running water, and lipid droplet formation was observed with an optical microscope. In addition, oil red O-stained cells are digitized under an optical microscope and accumulated in three different locations for each treatment using Lumina Vision Ver2.2.2 (Mitani Corporation), an image analysis and quantification software. The amount of sebum was quantified and expressed as an image unit (unit) indicating the amount.

1-4 Quantification of Cell Endothelial Lipid 1) Sample Preparation Method Drug-treated cells are washed twice with PBS (−) and collected using a 0.25% trypsin / 0.02% EDTA / PBS (−) solution. did. The obtained cell suspension was sonicated under ice cooling to disrupt the cells.

2) Method for measuring the amount of triacylglycerol The amount of triacylglycerol (TGs), which is the main component of sebum, was measured using Liquitec TGII (manufactured by Roche Diagnostics). That is, treatment sample 1 [1.65 IU / ml glycerol kinase / 6 IU / ml glycerol-3-phosphate oxidase / catalase / 2.95 μmol / ml disodium adenosine-5′-triphosphate, Trihydrate (ATP) /0.65 μmol / ml sodium N- (3,5-dimethoxyphenyl) -N′-succinylethylenediamine (DOSE)] and allowed to react at 37 ° C. for 10 minutes to give free glycerol. Removed. Treatment solution 2 [0.55 IU / ml lipoprotein lipase / peroxidase / 0.65 μmol / ml 4-aminoantipyrine (4-AA)] was immediately added, and the mixture was further reacted at 37 ° C. for 10 minutes. After completion of the reaction, absorbance at 590 nm was measured. The amount of TGs was calculated from the absorbance of the same triolein standard solution (0.6 mg / ml). The amount of DNA in the cell pulverized sample was measured using 3,5-diaminobenzoic acid dihydrochloride (DABA) method and calculated as the amount of TGs per 1 μg of DNA.

2. In vivo Experimental Method Three-week-old male golden hamster (purchased from Nippon SLC Co., Ltd., n = 1 per treatment), maitake extract or agaricus extract, 1, 2 and 4% by weight on the auricle (left ear) 50 μl of 95% ethanol / 5% glycerol containing was applied once a day. Moreover, the solvent was similarly applied to the control group (right ear). Two weeks later, frozen sections of hamster pinna were prepared and stained with Oil red O. A digital image of the tissue section of the auricle stained with oil red O under an optical microscope, and the amount of sebum in the hamster sebaceous gland is quantified using the image analysis and quantification software Lumina Vision. Expressed as:

3. Statistical processing
A significant difference test was performed between each treatment by Fisher's multivariate analysis of variance.

(result)
1. In vitro experiment (1) In hamster sebocytes (poorly differentiated type) in the insulin-untreated group, the maitake extract promoted the formation of intracellular lipid droplets (FIG. 1B, 400 μg / ml; contrast with FIG. A). It was also found that the lipid droplet formation promoting action by this maitake extract is concentration-dependent (FIG. 2). On the other hand, although Agaricus extract was weak, it promoted the formation of intracellular lipid droplets (FIG. 1C, 400 μg / ml; comparison with FIG. 1A and FIG. 2), but the promoting action was found to be significantly weaker than that of the maitake extract. (P <0.001).
(2) Similarly, in hamster sebocytes (differentiated type) treated with insulin, the maitake extract promoted the formation of intracellular lipid droplets in a concentration-dependent manner (FIG. 1E; comparison with FIG. 1D and FIG. 2). On the other hand, Agaricus extract also promoted the formation of intracellular lipid droplets under the same conditions (FIG. 1F; comparison with FIG. 1D and FIG. 2), but the promoting action was found to be significantly weaker than that of the maitake extract ( p <0.001).
(3) In hamster sebaceous cells in the insulin-untreated group, the maitake extract increased the amount of intracellular TGs in a concentration-dependent manner (FIG. 3). However, Agaricus extract did not affect the amount of intracellular TGs under the same conditions (FIG. 3). On the other hand, in the hamster sebaceous gland cells treated with insulin, the maitake extract similarly increased the amount of intracellular TGs in a concentration-dependent manner (FIG. 3). Agaricus extract also increased the amount of intracellular TGs, but at a concentration of 400 μg / ml, the amount was significantly lower than that of the maitake extract (FIG. 3).

2. In vivo experiment (1) Changes in body weight of hamsters before and after treatment with maitake extract and agaricus extract were as follows.

(2) Maitake extract significantly promoted sebum accumulation in sebaceous gland tissue 1.6, 3 and 1.3 times at concentrations of 1%, 2% and 4%, respectively (FIGS. 4 and 6A).

(3) Although 1% Agaricus extract suppressed sebum accumulation in sebaceous gland tissue, no significant change was observed in sebum accumulation at other concentrations (2% and 4%) (FIGS. 5 and 6A). .

(Discussion)
Maitake extract has a sebum production promoting effect in vivo and in vitro. It was also found that this promoting effect is stronger than Agaricus. In other words, the maitake extract is a powerful sebum production-promoting substance and is expected to be effective not only in the care of dry skin but also in reducing the pathological conditions of skin diseases caused by sebaceous gland function decline such as xerosis.

[Test Example 2]
Triacylglycerol (TGs) -specific production promoting effect of maitake pure ethanol extract (method)
1. Cultivation of hamster sebaceous cells Hamster sebaceous cells were seeded in a 35 mm culture dish at a cell number of 2.35 × 10 ⁴ cells / cm ² , and the maitake extract (100, 200, 400 μg / ml) obtained in Example 1 from the next day alone. Or a culture solution for sebaceous cells (SBCM) containing both maitake extract and insulin (10 nM) [DMEM / F-12 / 6% (v / v) fetal bovine serum / 2% (v / v) human serum / 0 .68 mM L-glutamine / penicillin G (100 units / ml) / streptomycin sulfate (100 μg / ml)] for 3 days. Cells were harvested after further culturing for 3 days in SBCM containing the same maitake extract alone or both maitake extract and insulin newly prepared 3 days later. Further, cells cultured in a culture solution containing no maitake extract and insulin were used as controls.

2. Sebum composition analysis Sebocytes cultured in the presence or absence of maitake extract were washed twice with PBS (−), and 0.25% (w / v) trypsin / 0.02% (w / v) EDTA / The solution was collected using 1.5 ml of PBS (−) solution. The obtained cell suspension was subjected to ultrasonic treatment (200 W, 6 seconds) for 5 minutes under ice-cooling using a sealed ultrasonic cell crusher (Bioruptor, manufactured by Cosmo Bio) for sebum composition analysis. A sample was used. The obtained sample was transferred to a degreased Spitz tube, and a chloroform: methanol (2: 1; v: v) solution was added to extract lipids. The quantification and composition analysis of the extracted lipid were performed using a thin layer chromatography automatic detection device (Iatroscan, manufactured by Diatron). That is, the extracted lipid was spotted on a rod-shaped thin layer (chromatrod) and first developed (1.5 cm) in a chloroform: methanol (35:35) solution, benzene: chloroform: acetic acid (50: 20: 0.7). ) Second development (8 cm) with the solution, and further third development (11 cm) with the hexane: benzene (35:35) solution. Next, the lipid component separated on the rod was directly detected by a flame ionization detector at room temperature under the condition of 30 seconds / rod.
The composition of each lipid is tripalmitin (corresponding to TG in FIG. 7), palmitic acid (corresponding to FFA in FIG. 7), cholesterol (corresponding to Cho in FIG. 7), used as known amounts of standard lipids, From the chromatograph corresponding to cholesterol palmitate (corresponding to ChoE in FIG. 7) (manufactured by Dothan Serdari Research) and palmityl palmitic acid (corresponding to WaxE in FIG. 7) (manufactured by Nucheck Prep) Analyzed. Each lipid amount was calculated from the peak area of cholesterol acetate (2 μg) (manufactured by Dothan Serdari Research) used as an internal standard.

(result)
From the results of sebum composition analysis, it was found that maitake extract (100, 200, 400 μg / ml) increased triacylglycerol (TG) in the sebum component preferentially and in a concentration-dependent manner (FIG. 7). In addition, treatment with 400 μg / ml maitake extract increased cholesterol ester (ChoE) and free fatty acid (FFA) levels, which were 2.2 and 5.3% of the total sebum, It became clear that it was extremely low compared with TG occupying 5%.

[Example 2]
A cosmetic cream containing a maitake extract was prepared with the following composition.
Ingredient name Compounding amount (% by weight)
Maitake extract 2.0
Olive oil 10.0
Tri (capryl / capric acid) glyceryl 10.0
Tocopherol 1.0
Purified water 77.0
Total 100.0

Example 3
A pharmaceutical cream containing a maitake extract was prepared with the following composition.
Ingredient name Compounding amount (% by weight)
Maitake extract 10.0
Olive oil 10.0
Tri (capryl / capric acid) glyceryl 10.0
Tocopherol 1.0
Purified water 69.0
Total 100.0

Example 4
Effect of Maitake Extract on Dry Skin Disease in Humans The effect on dry skin disease was examined using a cream containing 2% by weight of the Maitake extract shown in Example 2.

Test method Test subjects: 12 patients (6 men and 6 women) with psoriasis and desquamation (76 to 97 years old) in the geriatric health facility "Goodwell"
Implementation period: December 2006-January 2007 Method: A maitake extract-containing cream is applied to the subject's skin, and is divided into three stages based on desquamation (which means that the skin becomes keratinous and falls off) (3 : Severe, 2: moderate, 1: mild). The application site was the right lower arm, the left lower arm, the right lower leg, and the left lower leg, and the evaluation was performed for each site.

Results The following shows the degree of diagnostic evaluation of the skin condition of the subject for one week from the start of application (3: severe 2: moderate 1: mild). In addition, a diagnostic evaluation degree: 0 shows complete cure.

Subject 1
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
4/12/2006 2 1 2 2
2006/12/6 1 1 1 1
2006/12/8 1 1 1 1
2006/12/11 1 0 1 1

Subject 2
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2007/1/17 1 1 2 1
2007/1/19 1 1 1 1
2007/1/22 0 0 1 1
2007/1/24 0 0 1 1

Subject 3
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/6 2 2 2 3
2006/12/11 2 2 1 2
2006/12/13 1 0 0 0

Subject 4
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/15 1 1 1 1
2006/12/18 0 1 0 0
2006/12/20 0 1 0 0
2006/12/22 0 0 0 0

Subject 5
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2007/1/5 2 2 3 3
2007/1/8 1 1 2 2
2007/1/10 0 0 2 2
2007/1/12 0 0 2 2

Subject 6
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/18 0 1 3 2
2006/12/20 0 0 2 1
2006/12/25 0 0 1 1

Subject 7
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/18 1 1 1 1
2006/12/20 0 0 1 1
2006/12/22 0 0 1 1
December 25, 2006 0 0 0 1

Subject 8
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/29 2 3 3 3
2006/12/30 1 2 2 2
2007/1/4 1 0 2 1

Subject 9
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2007/1/5 0 0 2 3
2007/1/8 0 0 2 1
2007/1/10 0 0 2 1
2007/1/12 0 0 1 1

Subject 10
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/20 1 1 2 2
2006/12/22 1 0 2 2
2006/12/25 1 0 1 1
2006/12/26 1 0 1 1
2006/12/27 1 0 1 1

Subject 11
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
4/12/2006 1 1 2 1
2006/12/6 0 1 1 1
2006/12/8 0 1 1 1
2006/12/11 0 1 0 0

Subject 12
Examination date Right lower arm Left lower arm Right lower leg Left lower leg
2006/12/18 0 1 2 1
2006/12/20 0 0 1 1
2006/12/22 0 0 1 1
December 25, 2006 0 0 1 0

  Thus, the diagnostic evaluation degree of the skin state of the subjects 1 to 12 after the start of application showed improvement. Moreover, the significant symptom improvement effect by application | coating of the maitake extract containing cream was recognized 1-3 days after application | coating.

  FIG. 8 is a photograph of the skin before and after treatment of subject 5 with a maitake extract-containing cream. Treatment with the application of a cream containing Maitake extract improved dry skin symptoms.

  These results show that even a cosmetic cream having a maitake extract content of 2% by weight has a therapeutic effect on xeroderma.

  Since sebum production is promoted by the extract of the present invention, the composition of the present invention is useful as a cosmetic or a medicament for treating skin abnormalities / disorders or diseases caused by a decrease in sebum production.

Claims (3)

A method for producing a sebum production promoter , comprising extracting 100 parts by weight of dry maitake fruit bodies having a water content of 6% by weight or less with 400 to 1000 parts by weight of ethanol of 98.0% by volume or more. A method for producing a cosmetic for promoting sebum production, comprising extracting 100 parts by weight of a dried maitake fruit body having a water content of 6% by weight or less with 400 to 1000 parts by weight of ethanol of 98.0% by volume or more. . A method for producing a medicament for promoting sebum production, comprising extracting 100 parts by weight of a dried maitake fruit body having a water content of 6% by weight or less with 400 to 1000 parts by weight of ethanol of 98.0% by volume or more.